Genzyme Gets Mixed Results On Renvela Powder Formulation
This article was originally published in The Pink Sheet Daily
Executive Summary
An NDA for the tablet form of the follow-on chronic kidney disease therapy is pending at FDA.
You may also be interested in...
Genzyme Renal Division President John Butler: An Interview With “The Pink Sheet” DAILY
Butler speaks with the DAILY about the Renvela launch, plans for a next-generation phosphate binder and other candidates in the biotech’s renal pipeline.
Genzyme Renal Division President John Butler: An Interview With “The Pink Sheet” DAILY
Butler speaks with the DAILY about the Renvela launch, plans for a next-generation phosphate binder and other candidates in the biotech’s renal pipeline.
Genzyme’s Renvela Approved For Kidney Disease Patients On Dialysis
Filing for predialysis indication is on track for first half of 2008 after “positive” outcome of FDA Cardio-Renal Advisory Committee meeting, Genzyme Renal President Butler tells “The Pink Sheet” DAILY.